Inova Pharmaceuticals(australia) PT Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Inova Pharmaceuticals(australia) PT Pharmaceutical Import Records from India — 3 Products, $756.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Inova Pharmaceuticals(australia) PT — Pharmaceutical Importer Profile (2026) | 3 Products, $756.7K Trade | TransData Nexus

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bromhexine	Respiratory & OTC	$380.4K	17	2.3%	6
2	Codeine	Analgesics & Antipyretics	$257.3K	18	0.2%	17
3	Mebendazole	Antimalarial & Antiparasitic	$119.0K	24	0.9%	17

Inova Pharmaceuticals(australia) PT imports 3 pharmaceutical products across 3 categories into Australia totaling $756.7K.

Inova Pharmaceuticals(australia) PT — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Inova Pharmaceuticals (Australia) PT, officially known as iNova Pharmaceuticals Pty Ltd, is a prominent Australian pharmaceutical company specializing in the development, marketing, and distribution of both over-the-counter (OTC) and prescription medicines. The company is headquartered in Chatswood, New South Wales, Australia. iNova's extensive product portfolio spans therapeutic areas such as respiratory health, pain management, dermatology, and weight management, featuring well-known brands like Difflam, Duro-Tuss, Demazin, DermaVeen, Invisible Zinc, and Nyal.

In 2022, iNova Pharmaceuticals was acquired by leading private equity firms: TPG as the majority shareholder, and Pacific Equity Partners and Platinum Orchid, a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), as minority shareholders. This strategic acquisition has provided iNova with substantial investment strength and expertise, facilitating its growth and expansion in the global pharmaceutical market. (inovapharma.com.au)

2Distribution Network

iNova Pharmaceuticals operates a robust distribution network across Australia, ensuring efficient delivery of its products to various healthcare providers and consumers. The company's logistics capabilities are supported by a dedicated sales and marketing infrastructure serving pharmacy and healthcare channels. While specific warehouse locations are not publicly disclosed, iNova's strategic partnerships and supply chain management enable it to maintain a strong presence in the Australian market.

Beyond Australia, iNova Pharmaceuticals has established operations in key regions, including Asia-Pacific, Europe, the Middle East, and Africa. With products available in over 75 markets, the company leverages its global reach to deliver health solutions worldwide. (inovapharma.com.au)

3Industry Role

iNova Pharmaceuticals (Australia) PT functions as a primary wholesaler and distributor within Australia's pharmaceutical supply chain. The company imports a diverse range of finished pharmaceutical formulations from various international markets, including India, to meet the needs of the Australian healthcare sector. By managing the importation, distribution, and marketing of these products, iNova plays a crucial role in ensuring the availability of essential medicines to Australian consumers and healthcare providers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Inova Pharmaceuticals(australia) PT

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

iNova Pharmaceuticals imports a total of three products from India, encompassing three therapeutic categories. The top three products imported are Bromhexine, Codeine, and Mebendazole, with Bromhexine accounting for $380K (2.3% share), Codeine $257K (0.2% share), and Mebendazole $119K (0.9% share). This indicates a diversified sourcing strategy, as no single product dominates the import portfolio.

The shipment data reveals a total of 59 shipments from India, suggesting a stable and ongoing relationship between iNova Pharmaceuticals and its Indian suppliers. The absence of a single dominant product implies a strategic choice to mitigate risks associated with over-reliance on a particular supplier or product line. This approach enhances supply chain resilience and allows iNova to cater to a broader range of therapeutic needs within the Australian market.

2Supply Chain Resilience

iNova Pharmaceuticals' supply chain resilience is bolstered by its diversified sourcing strategy, importing a range of finished pharmaceutical formulations from multiple international suppliers, including India. This approach reduces dependency on a single source, mitigating potential disruptions. While specific details about backup suppliers and formulation diversity are not publicly disclosed, iNova's global operations and strategic partnerships suggest a robust framework designed to maintain consistent product availability.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory body responsible for overseeing the safety, efficacy, and quality of therapeutic goods, including medicines. The TGA operates under the Therapeutic Goods Administration Act 1989, which provides the legislative framework for regulating therapeutic goods in Australia. (tga.gov.au)

The marketing authorization pathway for Indian generics involves several key steps:

1. Australian Register of Therapeutic Goods (ARTG) Entry: Before importing a therapeutic good into Australia, it must be entered in the ARTG, unless exempt. This process involves submitting evidence of the product's safety, efficacy, and quality. (tga.gov.au)

2. Good Manufacturing Practice (GMP) Certification: Manufacturers must hold a valid GMP certificate recognized by the TGA or an equivalent authority. This certification ensures that manufacturing processes meet Australian standards. (tga.gov.au)

3. Import License: Importers must comply with TGA regulations when importing therapeutic goods, including obtaining necessary licenses and permits. (tga.gov.au)

2Import Licensing & GMP

Import licensing requirements in Australia are governed by the TGA. Importers must ensure that all imported therapeutic goods are entered in the ARTG, unless exempt. Additionally, importers must comply with TGA regulations when importing therapeutic goods, including obtaining necessary licenses and permits. (tga.gov.au)

Inova Pharmaceuticals(australia) PT — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

iNova Pharmaceuticals' focus on therapeutic areas such as respiratory health, pain management, dermatology, and weight management aligns with prevalent health concerns in Australia. The demand for products in these categories is driven by factors such as an aging population, increasing prevalence of chronic conditions, and a growing emphasis on health and wellness. By importing finished pharmaceutical formulations in these areas, iNova aims to meet the evolving needs of Australian consumers and healthcare providers.

2Sourcing Profile

iNova Pharmaceuticals employs a diversified sourcing strategy, importing finished pharmaceutical formulations from multiple international suppliers, including India. This approach allows the company to access a broad range of products, ensuring a comprehensive portfolio that addresses various therapeutic needs. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a valuable partner in iNova's procurement strategy.

3Market Positioning

Based on its product mix, iNova Pharmaceuticals serves multiple segments of the Australian market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse portfolio enables it to cater to a wide range of healthcare needs, positioning iNova as a key player in the Australian pharmaceutical distribution landscape.

Seller's Guide — How to Become a Supplier to Inova Pharmaceuticals(australia) PT

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with iNova Pharmaceuticals, particularly if they can offer high-quality finished pharmaceutical formulations that meet Australian regulatory standards. Gaps in iNova's current sourcing may exist in specific therapeutic areas or product forms, presenting potential avenues for collaboration.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Inova Pharmaceuticals(australia) PT

What products does Inova Pharmaceuticals(australia) PT import from India?

Inova Pharmaceuticals(australia) PT imports 3 pharmaceutical products across 3 categories. Top imports: Bromhexine ($380.4K), Codeine ($257.3K), Mebendazole ($119.0K).

What is Inova Pharmaceuticals(australia) PT's total pharmaceutical import value?

Inova Pharmaceuticals(australia) PT's total pharmaceutical import value from India is $756.7K, based on 59 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Inova Pharmaceuticals(australia) PT focus on?

Inova Pharmaceuticals(australia) PT imports across 3 categories. The largest: Respiratory & OTC (50.3%), Analgesics & Antipyretics (34.0%), Antimalarial & Antiparasitic (15.7%).

Get Full Inova Pharmaceuticals(australia) PT Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Inova Pharmaceuticals(australia) PT

Inova Pharmaceuticals(australia) PT — Import Portfolio & Supplier Network

What Products Does Inova Pharmaceuticals(australia) PT Import?

Top Products by Import Value

Inova Pharmaceuticals(australia) PT Therapeutic Categories — 3 Specializations